Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 720 DKK -1.1% Market Closed
Market Cap: 50.9B DKK
Have any thoughts about
Zealand Pharma A/S?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-39.5
Current
-15.9
Median
4.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-39.5
=
Enterprise Value
42.8B DKK
/
EBITDA
-1.1B DKK
All Countries
Close
Market Cap EV/EBITDA
DK
Zealand Pharma A/S
CSE:ZEAL
50.9B DKK -39.5
FR
Pharnext SCA
OTC:PNEXF
6T USD -220 140.1
US
Abbvie Inc
NYSE:ABBV
315.2B USD 15.4
US
Amgen Inc
NASDAQ:AMGN
141.9B USD 16.1
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD 21.5
US
Epizyme Inc
F:EPE
94.1B EUR -513.2
AU
CSL Ltd
ASX:CSL
135.7B AUD 19.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 15.4
US
Seagen Inc
F:SGT
39.3B EUR -58.6
NL
argenx SE
XBRU:ARGX
36B EUR -109.2
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBITDA: 16.4
Negative Multiple: -39.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 140.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16.1
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.5
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.2 N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.2 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-56.4
2-Years Forward
EV/EBITDA
97.6
3-Years Forward
EV/EBITDA
142.4

See Also

Discover More